NCT06756191

Antifungal Drugs in Pulmonary Mucormycosis

Evaluation on Efficacy and Safety of Liposomal Amphotericin B(AmBisome® ) Combination with Isavuconazole Versus AmBisome® Alone for Treatment of Patients with Pulmonary Mucormycosis

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 312 (estimated)
• Sponsor: Bin Cao · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of 5mg/kg/day combined with isavuconazole versus using AmBisome for the management of pulmonary mucormycosis

Conditions

• Pulmonary Mucormycosis

Interventions

Type	Name	Description
DRUG	Combination therapy group	Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
DRUG	Liposomal Amphotericin B	Liposomal amphotericin B (AmBisome®) alone

Timeline

• Start date: 2025-01-10
• Primary completion: 2025-07-10
• Completion: 2026-12-31
• First posted: 2025-01-01
• Last updated: 2025-01-01

Regulatory

• FDA-regulated drug study